Drug Trial Radar · NCT02832375
Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
Last checked: Nov 20, 2026Latest source record: May 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
242
Actual
Start
Mar 1, 2016
Primary completion
May 1, 2016
Study completion May 12, 2016
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This single center, comparative design study will be used to investigate the efficacy of an experimental stannous fluoride containing dentifrice in relieving dentinal hypersensitivity (DH) after short term use compared with a standard fluoride dentifrice.
Conditions
- Dentin Sensitivity
Interventions
stannous fluorideDrug
0.454% w/w stannous fluoride containing 1100ppm of fluoride
sodium monofluorophosphateDrug
0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Schiff Sensitivity Score on Day 3Time frame: Baseline, Day 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.